Drugs

, Volume 63, Issue 12, pp 1165–1184

Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

Therapy in Practice

Abstract

Besides genetic predisposition, obesity is the most important risk factor for the development of diabetes mellitus. Weight reduction has been shown to markedly improve blood glucose control and vascular risk factors associated with insulin resistance in obese individuals with type 2 diabetes. Therapeutic strategies for the obese diabetic patient include: (i) promoting weight loss, through lifestyle modifications (low-calorie diet and exercise) and antiobesity drugs (orlistat, sibutramine, etc.); (ii) improving blood glucose control, through agents decreasing insulin resistance (metformin or thiazolidinediones, e.g. pioglitazone and rosiglitazone) or insulin needs (α-glucosidase inhibitors, e.g. acarbose) in preference to agents stimulating defective insulin secretion (sulphonylureas, meglitinide analogues); and (iii) treating common associated risk factors, such as arterial hypertension and dyslipidaemias, to improve cardiovascular prognosis. Whenever insulin is required by the obese diabetic patient after failure to respond to oral drugs, it should be preferably prescribed in combination with an oral agent, more particularly metformin or acarbose, or possibly a thiazolidinedione. When morbid obesity is present, both restoring a good glycaemic control and correcting associated risk factors can only be obtained through a marked and sustained weight loss. This objective justifies more aggressive weight reduction programmes, including very-low-calorie diets and bariatric surgery, but only within a multidisciplinary approach and long-term strategy.

References

  1. 1.
    Scheen AJ. Obesity and diabetes. In: Kopelman PG, editor. The management of obesity and related disorders. London: Martin Dunitz Ltd, 2001: 11–44Google Scholar
  2. 2.
    Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427–34PubMedCrossRefGoogle Scholar
  3. 3.
    Scheen AJ, Lefèbvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology, oral antidiabetics. Berlin: Springer Verlag, 1996: 7–42Google Scholar
  4. 4.
    National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity and health risk. Arch Intern Med 2000; 160: 898–904CrossRefGoogle Scholar
  5. 5.
    Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 7: 761–811Google Scholar
  6. 6.
    Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effects on patients' risk. Obes Res 1998; 6 Suppl. 1: 8S–17SPubMedGoogle Scholar
  7. 7.
    Scheen AJ, Lefèbvre PJ. Insulin resistance versus insulin deficiency: which one comes first? The old question revisited. In: Di Mario U, Leonetti F, Pugliese G, et al., editors. Diabetes in the new millennium. New York: Wiley & Sons, 2000: 101–13Google Scholar
  8. 8.
    DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94PubMedCrossRefGoogle Scholar
  9. 9.
    Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23: 754–8PubMedCrossRefGoogle Scholar
  10. 10.
    Newburgh L. Control of hyperglycaemia of obese ‘diabetics’ by weight reduction. Ann Intern Med 1942; 17: 935–42Google Scholar
  11. 11.
    Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995; 3: 366–77Google Scholar
  12. 12.
    Brown SA, Upchurch S, Anding R, et al. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19: 613–24PubMedCrossRefGoogle Scholar
  13. 13.
    Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997; 20: 1744–66PubMedGoogle Scholar
  14. 14.
    Campbell L, Rössner S. Management of obesity in patients with Type 2 diabetes. Diabetic Med 2001; 18: 345–54PubMedCrossRefGoogle Scholar
  15. 15.
    Williams KV, Kelley DE. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000; 2: 121–9PubMedCrossRefGoogle Scholar
  16. 16.
    Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18: 1006–35PubMedCrossRefGoogle Scholar
  17. 17.
    Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499–504PubMedCrossRefGoogle Scholar
  18. 18.
    Scheen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev 1999; 7: 77–93Google Scholar
  19. 19.
    Hu FB, van Dam RM, Liu S. Diet and risk of type 2 diabetes: the role of types of fat and carbohydrate. Diabetologia 2001; 44: 805–17PubMedCrossRefGoogle Scholar
  20. 20.
    Franz MJ. Lifestyle modifications for diabetes management. Endocrinol Metab Clin North Am 1997; 26: 499–510PubMedCrossRefGoogle Scholar
  21. 21.
    Hamdy O, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30: 883–907PubMedCrossRefGoogle Scholar
  22. 22.
    Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2002; 25: 1722–8PubMedCrossRefGoogle Scholar
  23. 23.
    Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes in women. N Engl J Med 2001; 345: 790–7PubMedCrossRefGoogle Scholar
  24. 24.
    Tuomilehto J, Lindström J, Ericksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50PubMedCrossRefGoogle Scholar
  25. 25.
    Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403CrossRefGoogle Scholar
  26. 26.
    Gumbiner B. Treating obesity in type 2 diabetes: calories, composition, and control. Diabetes Care 1999; 22: 886–8PubMedCrossRefGoogle Scholar
  27. 27.
    American Diabetes Association. Position statement: nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 2001; 24 Suppl. 1: S44–7CrossRefGoogle Scholar
  28. 28.
    Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res 2001; 9 Suppl. 4: 348S–53SPubMedCrossRefGoogle Scholar
  29. 29.
    Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1: 113–9PubMedCrossRefGoogle Scholar
  30. 30.
    Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563–6PubMedCrossRefGoogle Scholar
  31. 31.
    Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med 1995; 12: 409–15PubMedCrossRefGoogle Scholar
  32. 32.
    Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397–415PubMedGoogle Scholar
  33. 33.
    Bosello O, Armellini F, Zamboni M, et al. The benefits of modest weight loss in type II diabetes. Int J Obes Relat Metab Disord 1997; 21 Suppl. 1: S10–3PubMedGoogle Scholar
  34. 34.
    Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749–53PubMedCrossRefGoogle Scholar
  35. 35.
    Ross R, Freeman JA, Janssen I. Exercise alone is an effective strategy for reducing obesity and related comorbidities. Exerc Sport Sci Rev 2000; 28: 165–70PubMedGoogle Scholar
  36. 36.
    Gautier JF, Scheen A, Lefèbvre PJ. Exercise in the management of non-insulin-dependent (type 2) diabetes mellitus. Int J Obes 1995; 19 Suppl. 4: S58–61Google Scholar
  37. 37.
    American Diabetes Association. Position statement: diabetes mellitus and exercise. Diabetes Care 1998; 21 Suppl. 1: S40–4Google Scholar
  38. 38.
    Albright A, Franz M, Hornsby G, et al. American College of Sports Medicine position stand: exercise and type 2 diabetes. Med Sci Sports Exerc 2000; 32: 1345–60PubMedCrossRefGoogle Scholar
  39. 39.
    Gudat U, Berger M, Lefèbvre PJ. Physical activity, fitness and non-insulin-dependent (type II) diabetes mellitus. In: Bouchard C, Shephard RJ, Stephens T, editors. Physical activity, fitness and health. Champaign (IL): Human Kinetics, 1994: 669–83Google Scholar
  40. 40.
    Blonk MC, Jacobs MAJM, Biesheuvel EHE, et al. Influences on weight loss in type 2 diabetic patients: little long-term benefit from group behaviour therapy and exercise training. Diabet Med 1994; 11: 449–57PubMedCrossRefGoogle Scholar
  41. 41.
    Sours NE, Frattali VP, Brand CD, et al. Sudden death associated with very low calorie weight reduction regimens. Am J Clin Nutr 1981; 34: 453–61PubMedGoogle Scholar
  42. 42.
    Wadden TA, Stunkard AJ, Brownell KD. Very low calorie diets: their efficacy, safety, and future. Ann Intern Med 1983; 99: 675–84PubMedGoogle Scholar
  43. 43.
    Wadden TA, Van Itallie TB, Blackburn GL. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA 1990; 263: 83–5PubMedCrossRefGoogle Scholar
  44. 44.
    Amatruda JM, Richeson JF, Welle SL, et al. The safety and efficacy of a controlled low-energy (very-low-calorie) diet in the treatment of non-insulin-dependent diabetes and obesity. Arch Intern Med 1988; 148: 873–7PubMedCrossRefGoogle Scholar
  45. 45.
    Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991; 14: 802–23PubMedCrossRefGoogle Scholar
  46. 46.
    Scheen AJ. Intérêts et limites de la diète protéique chez le patient obèse diabétique de type 2. Ann Endocrinol (Paris) 1999; 60: 443–50Google Scholar
  47. 47.
    Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287–93PubMedCrossRefGoogle Scholar
  48. 48.
    Wing RR, Blair EH, Bonomi P, et al. Caloric restriction per se is a significant factor in improvement in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17: 30–6PubMedCrossRefGoogle Scholar
  49. 49.
    Pontiroli AE, Calderara A, Pacchioni M, et al. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease. Diabetes Metab 1993; 19: 30–5Google Scholar
  50. 50.
    Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diabetes Metab 1998; 23: 116–23Google Scholar
  51. 51.
    Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120: 669–81PubMedCrossRefGoogle Scholar
  52. 52.
    Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25: 358–63PubMedCrossRefGoogle Scholar
  53. 53.
    Pontiroli AE, Pizzocri P, Cristina M, et al. Laprasocopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002; 87: 3555–61PubMedCrossRefGoogle Scholar
  54. 54.
    Pories WJ, MacDonald KG, Flickinger EG, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215: 633–43PubMedCrossRefGoogle Scholar
  55. 55.
    Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it: an operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339–52PubMedCrossRefGoogle Scholar
  56. 56.
    Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg 1998; 22: 936–46PubMedCrossRefGoogle Scholar
  57. 57.
    Sjöström CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477–84PubMedGoogle Scholar
  58. 58.
    Long SD, O'Brien K, MacDonald KG, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: a longitudinal intervention study. Diabetes Care 1993; 17: 372–5CrossRefGoogle Scholar
  59. 59.
    MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of noninsulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213–20PubMedCrossRefGoogle Scholar
  60. 60.
    Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev 1997; 5: 83–103Google Scholar
  61. 61.
    Scheen AJ, Lefèbvre PJ. Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord 1999; 23 Suppl. 1: 47–53PubMedCrossRefGoogle Scholar
  62. 62.
    Scheen AJ, Lefèbvre PJ. Pharmacological treatment of the obese diabetic patient. Diabete Metab 1993; 19: 547–59PubMedGoogle Scholar
  63. 63.
    Kosmiski L, Eckel RH. Anorectic agents in non-insulin dependent diabetes mellitus. Curr Opin Endocrinol Diab 1997; 4: 36–9CrossRefGoogle Scholar
  64. 64.
    Scheen AJ, Lefèbvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000; 16: 114–24PubMedCrossRefGoogle Scholar
  65. 65.
    Fernandez-Lopez JA, Remesar X, Foz M, et al. Pharmacological approaches for the treatment of obesity. Drugs 2002; 62: 915–44PubMedCrossRefGoogle Scholar
  66. 66.
    Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591–602PubMedCrossRefGoogle Scholar
  67. 67.
    Haddock CK, Posten WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262–73PubMedCrossRefGoogle Scholar
  68. 68.
    Redmon JB, Raatz SK, Kwong CA, et al. Pharmacological induction of weight loss to treat type 2 diabetes. Diabetes Care 1999; 22: 896–903PubMedCrossRefGoogle Scholar
  69. 69.
    Arnaud O, Nathan C. Antiobesity and lipid-lowering agents with antidiabetic activity. In: Bailey CJ, Flatt PR, editors. New antidiabetic drugs. London: Smith-Gordon, 1990: 133–42Google Scholar
  70. 70.
    Reaven GM. Insulin resistance, hyperinsulinemia and diabetes: contribution of benfluorex. Diabetes Metab Rev 1993; 9 Suppl. 1: S1–S72CrossRefGoogle Scholar
  71. 71.
    Ravel D. Benfluorex (MediatorR) et diabète non insulinodépendant. In: Selam J-L, editor. Journées de Diabétologie de l'Hôtel-Dieu. Paris: Flammarion Médecine-Sciences, 1997: 335–44Google Scholar
  72. 72.
    Bianchi R, Bongers V, Bravenboer B, et al. Effects of benfluorex on insulin resistance and lipid metabolism in obese Type II diabetic patients. Diabetes Care 1993; 16: 557–9PubMedCrossRefGoogle Scholar
  73. 73.
    Velussi M, Monte AD, Cernigoi AM. Therapeutic benefit of benfluorex in type II diabetic patients on diet regimen alone. J Diabetes Complications 1996; 10: 261–6PubMedCrossRefGoogle Scholar
  74. 74.
    Stucci N, de Gregoris P, Lavielle R, et al. Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas. J Diabetes Complications 1996; 10: 267–73PubMedCrossRefGoogle Scholar
  75. 75.
    Roger P, Auclair J, Drain P. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. J Diabetes Complications 1999; 13: 62–7PubMedCrossRefGoogle Scholar
  76. 76.
    Pontiroli AE, Pacchioni M, Piatti PM, et al. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J Clin Endocrinol Metab 1996; 81: 3727–32PubMedCrossRefGoogle Scholar
  77. 77.
    Leutenegger M, Bauduceau B, Brun JM, et al. Added benfluorex in obese insulin-requiring type 2 diabetes. Diabetes Metab 1998; 24: 55–61PubMedGoogle Scholar
  78. 78.
    Scheen AJ, Ernest Ph. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab (Paris) 2002; 28: 437–45Google Scholar
  79. 79.
    McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093–124PubMedCrossRefGoogle Scholar
  80. 80.
    James WPT, Astrap A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119–25PubMedCrossRefGoogle Scholar
  81. 81.
    VanGaal LF, Pfeiffer FW. The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord 2001; 25 Suppl. 4: S24–8PubMedCrossRefGoogle Scholar
  82. 82.
    Heath MJ, Chong E, Weinstein SP, et al. Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes [abstract]. Diabetes 1999; 48 Suppl. 1: A308CrossRefGoogle Scholar
  83. 83.
    Shepherd G, Fitchet M, Kelly F. Sibutramine: a meta-analysis of the change in fasting plasma glucose in patients with a high baseline fasting value (> 5.5 mmol/1) [abstract]. Int J Obes 1997; 21 Suppl. 2: S54Google Scholar
  84. 84.
    Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105–12PubMedCrossRefGoogle Scholar
  85. 85.
    Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175–87PubMedCrossRefGoogle Scholar
  86. 86.
    Gokcel A, Karakose H, Ertorer EM, et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957–60PubMedCrossRefGoogle Scholar
  87. 87.
    Serrano-Rios M, Mechionda N, Moreno Carretero E, et al. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabetic Med 2002; 19: 119–24PubMedCrossRefGoogle Scholar
  88. 88.
    Rissanen A, for the Finnish Multicentre Group. Sibutramine in the treatment of obese type II diabetics [abstract]. Int J Obes 1999; 23 Suppl. 5: S63Google Scholar
  89. 89.
    McNulty SJ, Ur E, Williams G, et al. A randomised trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125–31PubMedCrossRefGoogle Scholar
  90. 90.
    Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49–55PubMedCrossRefGoogle Scholar
  91. 91.
    McNeely W, Benfield P. Orlistat. Drags 1998; 56: 241–9CrossRefGoogle Scholar
  92. 92.
    Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–73PubMedCrossRefGoogle Scholar
  93. 93.
    Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42PubMedCrossRefGoogle Scholar
  94. 94.
    O'Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1–81Google Scholar
  95. 95.
    Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes 2001; 25: 1713–21CrossRefGoogle Scholar
  96. 96.
    Rosenfalck AM, Hendel H, Rasmussen MH, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 2002; 4: 19–28PubMedCrossRefGoogle Scholar
  97. 97.
    Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321–6PubMedCrossRefGoogle Scholar
  98. 98.
    Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245–54PubMedCrossRefGoogle Scholar
  99. 99.
    Scheen AJ. Prévention du diabète de type 2 chez le sujet obèse: premiers résultats avec l'orlistat dans l'étude XENDOS. Rev Med Liège 2002; 57: 617–21PubMedGoogle Scholar
  100. 100.
    Kelley DE, Jneidi M. Orlistat in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2002; 3: 599–605PubMedCrossRefGoogle Scholar
  101. 101.
    Keating GM, Jarvis B. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Drags 2001; 61: 2107–19CrossRefGoogle Scholar
  102. 102.
    Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288–94PubMedCrossRefGoogle Scholar
  103. 103.
    Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123–8PubMedCrossRefGoogle Scholar
  104. 104.
    Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003; 5: 180–8PubMedCrossRefGoogle Scholar
  105. 105.
    Deerochanawong C. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A433Google Scholar
  106. 106.
    Bonnici F. Effect of orlistat on glycemic control and body weight in overweight or obese South African patients with type 2 diabetes [abstract]. Diabetes 2002; 51 Suppl. 2: A412–3Google Scholar
  107. 107.
    Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415–22PubMedCrossRefGoogle Scholar
  108. 108.
    Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033–41PubMedCrossRefGoogle Scholar
  109. 109.
    Jacob S, Gomis R, Miles JM. Effect of orlistat on glycemic control in patients on or near maximal doses of oral anti-diabetic (OAD) medications [abstract]. Diabetes 2002; 51 Suppl. 2: A413Google Scholar
  110. 110.
    De Fronzo R, Pi-Sunyer FX. Effect of orlistat in patients with type 2 diabetes at differing baseline HbA1c levels [abstract]. Diabetes 2002; 51 Suppl. 2: A412Google Scholar
  111. 111.
    Rissanen A, Hollander P. Effect of orlistat on insulin resistance in patients with type 2 diabetes with baseline HbA1c levels > 8% [abstract]. Diabetes 2002; 51 Suppl. 2: A413Google Scholar
  112. 112.
    Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303–8PubMedCrossRefGoogle Scholar
  113. 113.
    Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997; 54: 355–68PubMedCrossRefGoogle Scholar
  114. 114.
    DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303PubMedGoogle Scholar
  115. 115.
    Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30: 909–33PubMedCrossRefGoogle Scholar
  116. 116.
    Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994; 17: 1542–4PubMedGoogle Scholar
  117. 117.
    American Diabetes Association. Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510–8Google Scholar
  118. 118.
    Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55: 225–36PubMedCrossRefGoogle Scholar
  119. 119.
    Groop LC. Sulfonylureas and NIDDM. Diabetes Care 1992; 15: 737–54PubMedCrossRefGoogle Scholar
  120. 120.
    Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, Zimmet P, DeFronzo RA, et al., editors. International textbook of diabetes mellitus. 2nd ed. Chichester: J Wiley, 1997: 817–40Google Scholar
  121. 121.
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRefGoogle Scholar
  122. 122.
    Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17: 411–25PubMedCrossRefGoogle Scholar
  123. 123.
    Owens DR. Repaglinide: prandial glucose regulator. A new class of oral antidiabetic drug. Diabet Med 1998; 15 Suppl. 4: S28–36PubMedCrossRefGoogle Scholar
  124. 124.
    Dunn CJ, Faulds D. Nateglinide. Drugs 2000; 60: 607–15PubMedCrossRefGoogle Scholar
  125. 125.
    Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755–72PubMedCrossRefGoogle Scholar
  126. 126.
    Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721–49PubMedCrossRefGoogle Scholar
  127. 127.
    Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99–110PubMedCrossRefGoogle Scholar
  128. 128.
    Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6: 89–131Google Scholar
  129. 129.
    Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999; 22: 33–7PubMedCrossRefGoogle Scholar
  130. 130.
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65CrossRefGoogle Scholar
  131. 131.
    Nagi D, Yudkin J. Effect of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621–9PubMedCrossRefGoogle Scholar
  132. 132.
    Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care 1994; 19: 920–6CrossRefGoogle Scholar
  133. 133.
    Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25–33PubMedGoogle Scholar
  134. 134.
    Genuth S. Implications of the United Kingdom Prospective Diabetes Study for patients with obesity and type 2 diabetes. Obes Res 2000; 8: 198–201PubMedCrossRefGoogle Scholar
  135. 135.
    Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28: 441–6PubMedCrossRefGoogle Scholar
  136. 136.
    Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406–12PubMedCrossRefGoogle Scholar
  137. 137.
    Fritsche A, Schmülling RM, Haring HU, et al. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000; 37: 13–8PubMedCrossRefGoogle Scholar
  138. 138.
    Hermann LS, Kalen J, Katzman P, et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 2001; 3: 428–34PubMedCrossRefGoogle Scholar
  139. 139.
    Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132–45Google Scholar
  140. 140.
    Scheen AJ. Clinical efficacy of acarbose in the treatment of diabetes: a critical review of controlled trials. Diabetes Metab 1998; 24: 311–20PubMedGoogle Scholar
  141. 141.
    Holman RR, Cull CA, Turner RC, et al. A randomized doubleblind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960–4PubMedCrossRefGoogle Scholar
  142. 142.
    Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49–56PubMedCrossRefGoogle Scholar
  143. 143.
    Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269–73PubMedCrossRefGoogle Scholar
  144. 144.
    Delgado H, Lehmann T, Bobbioni-Harsch E, et al. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195–200PubMedGoogle Scholar
  145. 145.
    Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–7PubMedCrossRefGoogle Scholar
  146. 146.
    Scheen AJ. Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003; 63(10): 933–51PubMedCrossRefGoogle Scholar
  147. 147.
    Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661–9PubMedCrossRefGoogle Scholar
  148. 148.
    Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–14PubMedCrossRefGoogle Scholar
  149. 149.
    Scheen AJ, Lefèbvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568–77PubMedCrossRefGoogle Scholar
  150. 150.
    Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805–37PubMedCrossRefGoogle Scholar
  151. 151.
    Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333–43PubMedCrossRefGoogle Scholar
  152. 152.
    Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867–72PubMedCrossRefGoogle Scholar
  153. 153.
    Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695–702PubMedCrossRefGoogle Scholar
  154. 154.
    Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395–409Google Scholar
  155. 155.
    Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796–803PubMedCrossRefGoogle Scholar
  156. 156.
    Scheen AJ. Glitazones et prise de poids. Ann Endocrinol (Paris) 2002; 63: S41–4Google Scholar
  157. 157.
    Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentrations but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470–4PubMedCrossRefGoogle Scholar
  158. 158.
    Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288–93PubMedCrossRefGoogle Scholar
  159. 159.
    Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067–71PubMedCrossRefGoogle Scholar
  160. 160.
    Katoh S, Hata S, Matsushima M, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy: a randomized controlled trial. Metabolism 2001; 50: 414–7PubMedCrossRefGoogle Scholar
  161. 161.
    Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obesity Res 2002; 10: 1008–15CrossRefGoogle Scholar
  162. 162.
    Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784–91PubMedCrossRefGoogle Scholar
  163. 163.
    Campbell IA. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000; 60: 1017–28PubMedCrossRefGoogle Scholar
  164. 164.
    Iavicoli M, Cucinotta D, De Mattia G, et al. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents. Diabet Med 1988; 5: 849–55PubMedCrossRefGoogle Scholar
  165. 165.
    Scheen AJ. Insulin therapy in the treatment of NIDDM. IDF Bull 1996; 41: 16–8Google Scholar
  166. 166.
    Randeree HA, Omar MAK, Motala AA, et al. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1993; 16: 1258–63Google Scholar
  167. 167.
    Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758–67PubMedCrossRefGoogle Scholar
  168. 168.
    Buse J. Combining insulin and oral agents. Am J Med 2000; 108 Suppl. 6A: 23S–32SPubMedCrossRefGoogle Scholar
  169. 169.
    Herman LS. Optimising therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 2000; 17: 283–94CrossRefGoogle Scholar
  170. 170.
    Yki-Järvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130: 389–96PubMedGoogle Scholar
  171. 171.
    Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107–12PubMedCrossRefGoogle Scholar
  172. 172.
    Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121: 928–35PubMedGoogle Scholar
  173. 173.
    Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928–32PubMedCrossRefGoogle Scholar
  174. 174.
    Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226–32PubMedCrossRefGoogle Scholar
  175. 175.
    Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251–7PubMedGoogle Scholar
  176. 176.
    Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51–61PubMedCrossRefGoogle Scholar
  177. 177.
    Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomised controlled trial. Diabetes Care 2003; 26: 784–90PubMedCrossRefGoogle Scholar
  178. 178.
    Riddle MC. Pramlintide: an agent for glycemic control plus weight control. Diabetes Technol Ther 2002; 4: 63–5PubMedCrossRefGoogle Scholar
  179. 179.
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570–81PubMedCrossRefGoogle Scholar
  180. 180.
    Yki-Järvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 2000; 60: 975–83PubMedCrossRefGoogle Scholar
  181. 181.
    Kjeldsen SE, Os I, Farsang C, et al. Treatment of hypertension in patients with type-2 diabetes mellitus. J Hypertens 2000; 18: 1345–56PubMedCrossRefGoogle Scholar
  182. 182.
    Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001; 135: 1079–83PubMedGoogle Scholar
  183. 183.
    Garg A, Grundy SM. Diabetic dyslipidemia and its therapy. Diabetes Rev 1997; 5: 425–33Google Scholar
  184. 184.
    Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am J Med 2002; 112 Suppl. 8A: 19S–26SPubMedCrossRefGoogle Scholar
  185. 185.
    Grant RW, Cagliero E, Murphy-Sheehy P, et al. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002; 112: 603–9PubMedCrossRefGoogle Scholar
  186. 186.
    Scheen AJ, VanGaal L, for the OCAPI Team. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI survey [abstract]. Diabetologia 2002; 45 Suppl. 2: A63Google Scholar
  187. 187.
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension 2001; 37: 1053–9PubMedCrossRefGoogle Scholar
  188. 188.
    Parving HH. Hypertension and diabetes: the scope of the problem. Blood Press 2001; 10 Suppl. 2: 25–31CrossRefGoogle Scholar
  189. 189.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Lancet 1998; 351: 1755–62PubMedCrossRefGoogle Scholar
  190. 190.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13CrossRefGoogle Scholar
  191. 191.
    UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microavascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 713–20CrossRefGoogle Scholar
  192. 192.
    Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–5PubMedCrossRefGoogle Scholar
  193. 193.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53PubMedCrossRefGoogle Scholar
  194. 194.
    Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10PubMedCrossRefGoogle Scholar
  195. 195.
    Pyörälä K, Pedersen TE, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614–20PubMedCrossRefGoogle Scholar
  196. 196.
    Heart Protection Study Collaborative Group MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–23CrossRefGoogle Scholar
  197. 197.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–8PubMedCrossRefGoogle Scholar
  198. 198.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9PubMedCrossRefGoogle Scholar
  199. 199.
    Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9 Suppl. 4: 326S–34SPubMedCrossRefGoogle Scholar
  200. 200.
    UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–58CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Division of Diabetes, Department of MedicineNutrition and Metabolic Disorders, CHU Sart TilmanLiègeBelgium

Personalised recommendations